Overall, all but one tumor (66/67) had at least one well-established driver gene mutation (Fig. 6a), i.e. MAPK pathway (NF1, NRAS, KIT, BRAF), SF3B1, TP53 and MDM2, SPRED1, TERT and ATRX, CDK4 and CCND1 (Fig. 6b). This evidence concerns the gene ATRX and neoplasm.